CRYOFOCUS-B released its 2024 annual performance, with a shareholder attributable loss of 104 million yuan, an increase of 7.1% year-on-year
I'm PortAI, I can summarize articles.
CRYOFOCUS-B released its 2024 annual performance, with revenue of 53.531 million yuan, a year-on-year increase of 30.7%. However, the loss attributable to the parent company owners was 104 million yuan, an increase of 7.1% year-on-year, with a basic loss per share of 0.44 yuan. The revenue growth was mainly due to the increase in sales of the cardiac cryoablation system, cryoadhesion treatment system, and other respiratory intervention products
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments